Rapport Therapeutics, Inc.
RAPP
$47.42
$0.060.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.00M | 20.00M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.00M | 20.00M | -- | -- | -- |
| Cost of Revenue | 84.13M | 55.40M | 42.25M | 42.25M | 42.25M |
| Gross Profit | -64.13M | -35.40M | -42.25M | -42.25M | -42.25M |
| SG&A Expenses | 36.85M | 34.27M | 30.31M | 28.38M | 26.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 173.52M | 142.21M | 125.10M | 110.11M | 101.77M |
| Operating Income | -153.52M | -122.21M | -125.10M | -110.11M | -101.77M |
| Income Before Tax | -137.16M | -107.28M | -111.48M | -97.70M | -88.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -137.16 | -107.28 | -111.48 | -97.70 | -88.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.16M | -107.28M | -111.48M | -97.70M | -88.31M |
| EBIT | -153.52M | -122.21M | -125.10M | -110.11M | -101.77M |
| EBITDA | -152.56M | -121.21M | -124.08M | -109.10M | -100.79M |
| EPS Basic | -3.04 | -2.60 | -2.87 | -2.72 | -2.51 |
| Normalized Basic EPS | -1.90 | -1.63 | -1.79 | -1.70 | -1.57 |
| EPS Diluted | -3.04 | -2.60 | -2.87 | -2.72 | -2.51 |
| Normalized Diluted EPS | -1.90 | -1.63 | -1.79 | -1.70 | -1.57 |
| Average Basic Shares Outstanding | 179.62M | 167.59M | 155.62M | 143.71M | 140.64M |
| Average Diluted Shares Outstanding | 179.62M | 167.59M | 155.62M | 143.71M | 140.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |